Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

Xilio plans to bring its two lead immuno-oncology candidates to clinical proof-of-concept data, as well as advance its earlier stage programs, with a tranched $100.5 million series B.

Takeda Ventures Inc. led the financing with participation from fellow new investors SV Health Investors, MRL Ventures Fund, RiverVest Venture Partners, Bay City Capital, Solasta Ventures, M Ventures and Ipsen Ventures; and existing syndicate members F-Prime Capital and Atlas Venture and additional undisclosed investors...